|
|
|
|
|
| June 11,
2010 | ISSUE NUMBER 152 VOL 8 |
Strategy
Merck Reveals New Trial Network for Oncology
Merck has established a stable of 15 to 20 investigators focused solely on cancer compounds in an effort to boost efficiency and help move along the bevy of oncology products the firm has in its pipeline.
R&D
Avastin Gets Boost from New Data
Genentech’s cancer treatment Avastin was found to be effective in decreasing the progression of ovarian cancer in Phase II trials. This is great news for Roche, which spent billions to purchase the biotech giant.
Advertisement:
Does anybody in Life Sciences do Call & Territory Planning?
It’s been a problem for years, so you have to see this! Using update’s virtually automatic CRM tool means being analytical and efficient while rewarding for the reps. Speed, efficiency, convenience, and intelligence, for optimal business results and a better ROI. Take a look at business cases, the functionality and advantages that make you more competitive than ever! Join the free webinar –
 Register NOW!
|
Sales
Physicians Not on the Move
A new study indicates that doctors are no longer switching offices—largely due to current economic woes. What does this mean for sales reps? Pharm Exec interviews SK&A to find out more about its survey.
Security
Murky EU Definition of ‘Counterfeit’ Set to Hit Pharma
Paul McClenaghan looks at how the UK high court’s recent decision regarding a shipment of fake Nokia phones could have serious ramifications for the transit of pharmaceuticals in Europe.
Guest Blog
Elmendorf Refuses to Go Quietly into the Night of HCR
Amidst all the gurgling of oil last week (bad! bad! bad!), a competing thunderstorm of words erupted as Doug Elmendorf, Director of CBO, had the temerity to revisit the real costs of the new HCR law.
New & Noteworthy
The 2010 Pharm Exec 50
One year after the rash of pharma megamergers, Pharm Exec's annual listing of the industry's top-selling companies looks a little different. Find out who disappeared from the list, and what up-and-coming companies finally broke into the top 50.
|
| 
|
 // Biodel added Donald Casey to its board.
// Edward Connor was appointed chief medical officer at 3-V Biosciences.
// YM BioSciences filled its newly created position of president and COO with Nick Glover.
// Anthera Pharmaceuticals promoted Colin Hislop to chief medical officer.
// Talecris Biotherapeutics upped John Perkins to EVP of global commercial operations. He had been SVP and general manager, portfolio management and US business.// Par Pharmaceutical treasurer Michael Tropiano will replace Lawrence Kenyon as CFO.// Paul Berns joined Jazz Pharmaceuticals’ board.// Phytomedics added Jacques-Pierre Moreau to its board.// Ikaria appointed Geoffrey Nichol to the newly created position of chief medical officer.
|
Advertisement:
The Health Care Reform Opportunity: Implications and Recommendations for Life Sciences
Is health care reform a tough pill to swallow for your business? Although reform is changing the landscape, it is rife with opportunity. A report from Capgemini Consulting examines the challenges and implications resulting from health care reform and offers recommendations on how capitalize on the shifts within the industry.
 Download here
|
|
June 13–17, 2010 Drug Industry Association’s Annual Meeting
Washington DC
Jun 22–23 Disease Education and Bio/Pharmaceutical Product Promotion Using Social Media Tools
Alexandria, VA
Jun 28–29 Clinical R&D Compliance Forum
Philadelphia, PA
Jul 26–27 Bio/Pharmaceutical Summit: Optimize Market Research and to Drive Accurate Product Forecasts
Philadelphia, PA
Jul 29–30 5th Annual Congress on Clinical Supply Chain Management
Princeton, NJ
Sep 9–10 Clinical Trials in Latin America
Lima, Peru
Sep 29–30 6th Annual Bio/Pharmaceutical and Medical Device Product Recalls Summit
Washington, DC
|
|
|
|
 |
|
 |
|
 |
| A year and a half into President Obama's tenure, how do you view the effectiveness of the "new" FDA? |
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To
ensure delivery to your Inbox, please add us to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
